佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688198 佰仁医疗

已收盘 11-15 15:00:00

{"stockData":{"symbol":"688198","market":"SH","secType":"STK","nameCN":"佰仁医疗","latestPrice":117.03,"timestamp":1731654000000,"preClose":120,"halted":0,"volume":328126,"delay":0,"floatShares":137000000,"shares":137000000,"eps":0.7537,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.97,"latestTime":"11-15 15:00:00","open":119.58,"high":120.6,"low":117.01,"amount":38936500,"amplitude":0.0299,"askPrice":117.18,"askSize":15,"bidPrice":117.03,"bidSize":93,"shortable":0,"etf":0,"ttmEps":0.7537,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731893400000},"adr":0,"adjPreClose":120,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":132,"lowLimit":108,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":137395148,"pbRate":13.72,"roa":"--","roe":"4.97%","epsLYR":0.85,"committee":0.821306,"marketValue":16079000000,"floatMarketCap":16079000000,"peRate":155.273978,"changeRate":-0.0247,"turnoverRate":0.0024,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-18。","afterMarket":{"amount":0,"volume":0,"close":117.03,"buyVolume":0,"sellVolume":0,"time":1731656039464,"indexStatus":"已收盘 11-15 15:30:00","preClose":120}},"requestUrl":"/m/hq/s/688198","defaultTab":"news","newsList":[{"id":"2483322360","title":"佰仁医疗：11月14日高管金磊增持股份合计1.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483322360?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:01","pubTimestamp":1731672097,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月15日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年11月14日公司董事金磊共增持公司股份1.2万股，占公司总股本为0.0087%。变动期间公司股价下跌3.83%，11月14日当日收盘报120.0元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500038427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2481424391","title":"佰仁医疗：分体式介入二尖瓣已经进入以注册为目的的动物试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2481424391","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481424391?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:39","pubTimestamp":1731055189,"startTime":"0","endTime":"0","summary":"近日，佰仁医疗举办2024年第三季度业绩说明会。经导管主动脉瓣系统基于佰仁医疗独有的专利创新技术设计，传承了经大组长期临床验证的瓣膜卓越耐久性，适配未来接续治疗的支架二次可扩性，优化了瓣膜病全生命周期管理。公司分体式介入二尖瓣已经进入以注册为目的的动物试验阶段，进展顺利，按规定和进程应在明年一至二季度完成术后观察，依据试验结果制定临床试验方案和计划临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108164003a22383ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108164003a22383ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2480301720","title":"佰仁医疗：11月1日高管金磊增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480301720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480301720?lang=zh_cn&edition=full","pubTime":"2024-11-04 20:01","pubTimestamp":1730721687,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月4日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年11月1日公司董事,高级管理人员,核心技术人员金磊共增持公司股份2000.0股，占公司总股本为0.0015%。佰仁医疗近半年内的董监高及核心技术人员增减持详情如下：佰仁医疗的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出624.94万，融资余额减少；融券净流入0.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400028279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2479083685","title":"佰仁医疗：10月30日高管金磊增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479083685?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:01","pubTimestamp":1730376076,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月31日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年10月30日公司董事,高级管理人员,核心技术人员金磊共增持公司股份2000.0股，占公司总股本为0.0015%。变动期间公司股价下跌1.63%，10月30日当日收盘报120.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100040916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2479295726","title":"中银证券：给予佰仁医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479295726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479295726?lang=zh_cn&edition=full","pubTime":"2024-10-31 14:40","pubTimestamp":1730356845,"startTime":"0","endTime":"0","summary":"中银国际证券股份有限公司刘恩阳,薛源近期对佰仁医疗进行研究并发布了研究报告《收入端增速稳定，看好新产品未来业绩增量》，本报告对佰仁医疗给出买入评级，当前股价为119.84元。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为111.83。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100023985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601696","688198"],"gpt_icon":0},{"id":"2479349562","title":"图解佰仁医疗三季报：第三季度单季净利润同比减10.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479349562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479349562?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:20","pubTimestamp":1730222409,"startTime":"0","endTime":"0","summary":"证券之星消息，佰仁医疗2024年三季报显示，公司主营收入2.92亿元，同比上升13.57%；归母净利润5869.34万元，同比下降16.56%；扣非净利润5531.16万元，同比下降10.85%；其中2024年第三季度，公司单季度主营收入1.02亿元，同比上升13.25%；单季度归母净利润2350.27万元，同比下降10.04%；单季度扣非净利润2274.76万元，同比下降5.83%；负债率9.27%，投资收益763.21万元，财务费用-376.45万元，毛利率88.56%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000000739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2479312912","title":"佰仁医疗公布三季报 前三季净利减少16.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479312912","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479312912?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:10","pubTimestamp":1730221800,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　10月30日消息，佰仁医疗发布三季度报告。　　公告显示，公司前三季度营业收入292,324,016.69元，同比增加13.57%，归属上市公司股东的净利润58,693,362.23元，同比减少16.56%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-30/doc-incufzcn1642571.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-30/doc-incufzcn1642571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2478175860","title":"佰仁医疗最新公告：胶原纤维填充剂-I注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2478175860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478175860?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:25","pubTimestamp":1730103913,"startTime":"0","endTime":"0","summary":"佰仁医疗公告，控股子公司北京艾佰瑞生物技术有限公司研制的胶原纤维填充剂-I注册申请获国家药品监督管理局正式受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2478676785","title":"佰仁医疗10月25日主力资金流出299万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478676785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478676785?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:18","pubTimestamp":1729840730,"startTime":"0","endTime":"0","summary":"10月25日, 佰仁医疗股价涨0.54%，报收127.37元，成交金额3414万元，换手率0.20%，振幅2.69%，量比0.47。佰仁医疗今日主力资金净流出299万元，连续5日净流出，上一交易日主力净流出267万元，今日环比增加11.99%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为25.00%，平均跌幅为0.66%。该股近5个交易日下跌4.41%，主力资金累计净流出1567万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出7327万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153143ab72bea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153143ab72bea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵，如何低门槛布局科创板？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告，业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户，且满足交易风险评级要求，即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688139","688318","688409","688177","688352","688548","688700","688110","688200","688568","688198","688608","688779","688141","688778","688425","688289","688549","688322","688029","688336","688232","588030","688161","688166","688432","688347","688192","688019","688348","688032","688484","688690","688578","688575","688083","688278","688062","688235","688266","688106","688617","688153","688016","688702","000698","688433","688281","688037","688556","688208","688147","688326","688408","688005","688361","688498","688400","688027","688017","688390","688366","688526","688048","688686","688050","688066","688063","688105","688276","688055","688172","688443","688107","688248","688146","688387","688439","688052","688001","688088","688331","688772","688520","688097","688739","688536","688100","688213","688007","688612","688343","159982","688002","688333","688582","688717","688567","688639","688789","688798","688327","688516","688006"],"gpt_icon":0},{"id":"2476447925","title":"佰仁医疗大幅上涨 获主力净流入434万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476447925","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476447925?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:13","pubTimestamp":1729228401,"startTime":"0","endTime":"0","summary":"10月18日，佰仁医疗股价大幅上涨，截至13点13分，佰仁医疗上涨5.42%，报129.65元/股，成交6544万元，换手率0.38%。资金动向截止发稿，佰仁医疗获得主力净流入434万元，其中超大单流入989万元，大单流出555万元。最新财报显示，今年中报，佰仁医疗实现营业收入1.91亿元，同比增长13.74%，净利润为3,519.07万元，同比减少20.42%，基本每股收益为0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132438ab6b09b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132438ab6b09b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2475513030","title":"佰仁医疗大跌5.41% 获主力净流入增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2475513030","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475513030?lang=zh_cn&edition=full","pubTime":"2024-10-15 14:23","pubTimestamp":1728973425,"startTime":"0","endTime":"0","summary":"10月15日，佰仁医疗股价大幅下跌，截至14点23分，佰仁医疗下跌5.41%，报120.00元/股，成交7324万元，换手率0.43%，振幅6.28%。资金动向截止发稿，佰仁医疗获得主力净流出992万元，其中超大单流出1083万元，大单流入92万元。最新财报显示，今年中报，佰仁医疗实现营业收入1.91亿元，同比增长13.74%，净利润为3,519.07万元，同比减少20.42%，基本每股收益为0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015142412a1e0bbb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015142412a1e0bbb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2475340727","title":"皮海洲：倍受市场关注的首单“增持贷”何以流产了？ | 立方大家谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2475340727","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475340727?lang=zh_cn&edition=full","pubTime":"2024-10-15 06:53","pubTimestamp":1728946405,"startTime":"0","endTime":"0","summary":"皮海洲 | 立方大家谈专栏作者10月7日晚，在科创板上市的佰仁医疗公司发布的《关于控股股东、实际控制人增持公司股份计划的公告》受到市场的广泛关注。如此一来，佰仁医疗控股股东的增持计划就成了首单响应“增持贷”的项目。而“增持贷”无疑是近期央行政策的一大亮点。而“增持贷”10月8日银行方面还没有正式推出，而且截止10月11日为止，银行方面仍然还没有正式推出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101506581695a8165d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101506581695a8165d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2474229739","title":"佰仁医疗大跌6.33% 6家券商给予买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474229739","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474229739?lang=zh_cn&edition=full","pubTime":"2024-10-10 09:30","pubTimestamp":1728523804,"startTime":"0","endTime":"0","summary":"10月10日，佰仁医疗股价大幅下跌，截至09点30分，佰仁医疗下跌6.33%，报146.60元/股，成交403万元，换手率0.02%，振幅2.30%。此外，数据统计显示，近半年内6家券商给予买入建议。资金动向截止发稿，佰仁医疗获得主力净流出97万元，其中超大单流出168万元，大单流入72万元。最新财报显示，今年中报，佰仁医疗实现营业收入1.91亿元，同比增长13.74%，净利润为3,519.07万元，同比减少20.42%，基本每股收益为0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010093051ab68fb30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010093051ab68fb30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2474216528","title":"佰仁医疗涨12.44%，西南证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2474216528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474216528?lang=zh_cn&edition=full","pubTime":"2024-10-09 17:02","pubTimestamp":1728464539,"startTime":"0","endTime":"0","summary":"今日佰仁医疗涨12.44%，收盘报156.5元。2024年8月26日，西南证券研究员杜向阳发布了对佰仁医疗的研报《2024年中报点评：球扩TAVR及球扩介入瓣中瓣放量在即，打造瓣膜病全生命周期管理》，该研报对佰仁医疗给出“买入”评级。作为以动物源性植（介）入材料为平台的创新龙头，未来潜力较大，维持“买入”评级。佰仁医疗个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900030511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","688198"],"gpt_icon":0},{"id":"2474230359","title":"佰仁医疗创近2年新高 6家券商给予买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474230359","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474230359?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:30","pubTimestamp":1728437403,"startTime":"0","endTime":"0","summary":"10月09日，佰仁医疗股价大幅上涨，截至09点30分，佰仁医疗上涨13.52%，报158.00元/股，创近2年新高，成交5493万元，换手率0.24%，振幅5.75%。此外，数据统计显示，近半年内6家券商给予买入建议。资金动向截止发稿，佰仁医疗获得主力净流出1382万元，其中超大单流出1654万元，大单流入272万元。最新财报显示，今年中报，佰仁医疗实现营业收入1.91亿元，同比增长13.74%，净利润为3,519.07万元，同比减少20.42%，基本每股收益为0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009093148ab689fc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009093148ab689fc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2474293346","title":"佰仁医疗开盘涨停 董事长直接持股浮盈近20亿元 回应拟增持股票：公司股价被低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2474293346","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474293346?lang=zh_cn&edition=full","pubTime":"2024-10-08 22:18","pubTimestamp":1728397080,"startTime":"0","endTime":"0","summary":"10月8日，佰仁医疗开盘涨停。消息面上，公司前一晚发布公告称，实际控制人金磊拟使用自有或自筹资金，增持公司股份。董事长称公司股价被低估其直接持股单日浮盈近20亿元佰仁医疗此次公告备受外界关注，一定程度上源于金磊的大股东身份和其计划的回购力度。自2024年10月8日起6个月内，金磊计划增持10万股起，本次增持不设增持股份价格的上限及下限。而根据佰仁医疗2024年半年报，公司硬脑脊膜、疝补片已纳入集采范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100822211095987f7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100822211095987f7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2473441814","title":"佰仁医疗修改公告 实控人不使用“增持贷” 以自有资金增持股份？","url":"https://stock-news.laohu8.com/highlight/detail?id=2473441814","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473441814?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:52","pubTimestamp":1728381120,"startTime":"0","endTime":"0","summary":"10月7日晚，科创板上市公司佰仁医疗公告，为响应央行政策，控股股东、实控人金磊拟使用专项贷款资金增持公司股份。据南都湾财社报道，佰仁医疗此前表示，修改公告系应监管机构要求，此次增持资金来源仍将为专项贷款。金磊还承诺，本次增持完成后12个月内不减持其持有的公司股份。若按照10月8日收盘价计算，金磊最高增持213万股佰仁医疗股份，需要拿出约2.96亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvwyw7069730.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvwyw7069730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2473418236","title":"A股首家“贷款增持”公司改口，佰仁医疗称实控人拟以“自有或自筹资金”增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2473418236","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473418236?lang=zh_cn&edition=full","pubTime":"2024-10-08 14:42","pubTimestamp":1728369755,"startTime":"0","endTime":"0","summary":"不过佰仁医疗随后在上交所重发公告称上述增持“拟使用自有或自筹资金”，引发市场关注。在被问及该增持计划的资金安排时，佰仁医疗回应路透称以“当前上交所公告为准”，即上述增持拟使用自有或自筹资金。不过随后其在上交所官网重发公告称，实际控制人为了响应央行的政策引导，“拟使用自有或自筹资金”增持公司A股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nL4S3LK0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2473462544","title":"佰仁医疗涨停创10个月新高 我国医疗器械产业成绩显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2473462544","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473462544?lang=zh_cn&edition=full","pubTime":"2024-10-08 09:30","pubTimestamp":1728351002,"startTime":"0","endTime":"0","summary":"10月08日，佰仁医疗股价大幅上涨，截至09点30分，佰仁医疗触及涨停，报139.18元/股，创近10个月新高，成交152万元，换手率0.01%。国家药监局近日通报4起医疗器械网络销售违法违规案件信息(第七批)。数据显示，今年前8个月，国家药监局批准的创新医疗器械数量达到46个，同比增长12.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008110630a1dee156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008110630a1dee156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688198","BK0251","159883"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-12-09","address":"北京市昌平区科技园东区华昌路2号","stockEarnings":[{"period":"1week","weight":-0.0666},{"period":"1month","weight":-0.0493},{"period":"3month","weight":0.1952},{"period":"6month","weight":0.0739},{"period":"1year","weight":-0.1655},{"period":"ytd","weight":-0.0533}],"companyName":"北京佰仁医疗科技股份有限公司","boardCode":"AI0035","perCapita":"55919股","boardName":"专用设备制造业","registeredCapital":"13739万元","compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.056},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.1196}],"survey":"　　北京佰仁医疗科技股份有限公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新技术企业,主要产品主要包括心脏瓣膜置换与修复、先天性心脏病植介入治疗、外科软组织修复等。","serverTime":1731737798839,"listedPrice":23.68,"stockholders":"2457人(较上一季度减少1.64%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佰仁医疗,688198,佰仁医疗股票,佰仁医疗股票老虎,佰仁医疗股票老虎国际,佰仁医疗行情,佰仁医疗股票行情,佰仁医疗股价,佰仁医疗股市,佰仁医疗股票价格,佰仁医疗股票交易,佰仁医疗股票购买,佰仁医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}